Compare

Basilea Pharmaceutica AG/€BSLN

1D1W1MYTD1Y5YMAX

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a biopharmaceutical company headquartered in Basel, Switzerland. The company focuses on the research, development, and commercialization of innovative medicines, primarily in the areas of infectious diseases and oncology. Some of its key products include antifungal and antibiotic treatments like Cresemba and Zevtera, which address significant medical needs in their respective markets. Basilea was founded as a spin-off from Roche in 2000, reflecting its strong roots in pharmaceutical research. The company's strategic positioning capitalizes on its expertise in addressing drug-resistant bacterial infections and rare fungal infections, providing solutions where few alternatives exist. Basilea operates on a global scale, collaborating with international partners to expand its research and market reach.
Ticker
€BSLN
Sector
Health
Primary listing
XGAT
Employees
200
Headquarters
Allschwil, Switzerland
Website
www.basilea.com

BSLN Metrics

BasicAdvanced
€890M
16.70
€4.30
0.43
-

Bulls say / Bears say

Basilea delivered strong H1 2026 momentum, with revenue up 14% to CHF 119.0 million, operating profit up 32% to CHF 31.6 million, and net profit up 77% to CHF 27.9 million; it also raised its full-year operating-profit growth guidance to approximately 40%. (Basilea Pharmaceutica)
The commercial franchise is scaling: global in-market Cresemba sales rose 27% year over year, while the U.S. rollout of Zevtera is gaining hospital adoption; Basilea now expects Cresemba- and Zevtera-related revenue of approximately CHF 210 million in 2026. (Basilea Pharmaceutica)
Financial flexibility has improved materially: cash and restricted cash reached CHF 176.0 million at June 30, 2026, net cash rose to CHF 105.3 million, and outstanding debt was reduced to CHF 71.0 million, supporting further pipeline investment without immediate equity financing pressure. (Basilea Pharmaceutica)
R&D spending rose 41% year over year to CHF 54.0 million in H1 2026, while operating cash flow declined to CHF 19.0 million from CHF 23.1 million, indicating that pipeline investment and working-capital needs are absorbing cash. (Basilea Pharmaceutica)
Fosmanogepix remains a long-dated, binary value driver: Phase 3 data and the planned regulatory submission are not expected until 2028, leaving meaningful clinical, regulatory, and execution risk before potential commercialization. (Basilea Pharmaceutica)
The revenue mix is increasingly dependent on contract and other revenue: in H1 2026, contract revenue of CHF 62.4 million exceeded product revenue of CHF 29.9 million, exposing results to partner performance, milestone timing, and external funding flows. (Basilea Pharmaceutica)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.